Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.
The event will offer investors and analysts an in-depth look at the Company's long-term strategy, product roadmap, and financial outlook, as well as a Q&A session with the executive leadership team.
"Biopharma companies are rethinking how they develop medicines—prioritizing greater predictability, transparency, and scientific rigor at every step. Simulations Plus sits at the intersection of these needs," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "We are committed to helping our clients navigate this complexity with clarity and confidence. During Investor Day, we will demonstrate how our unified strategy positions us to support the next era of innovation in drug development."
Attendees will gain insight into Simulations Plus' vision for an integrated, AI-enabled modeling ecosystem spanning discovery, development, clinical operations, and commercialization. The agenda will include updates on:
- The industry environment and the accelerating adoption of model-informed drug development (MIDD)
- The Company's unified product and technology strategy
- Advances in scientific services supporting client workflows across the drug lifecycle
- Financial priorities and outlook
The event will be webcast live, and a replay will be posted following the event.
Event Details
- Date: Wednesday, January 21, 2026
- Time: 1:00 PM ET – 2:30 PM ET
- Location: Virtual
- Webcast Registration: Here
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.
Environmental, Social, and Governance
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218867761/en/
Investor Relations Contact:
Lisa Fortuna
Financial Profiles
310-622-8251
[email protected]